Authors:
O.A. Gromova 1.2 , I.Yu. Torshin 2 , L.E. Fedotova 1
1 FSBEI in the "Ivanovo State Medical Academy", Ivanovo;
2 FSBI "Federal Research Center" Informatics and Management "of the Russian Academy of Sciences, Moscow
Authors:
O.A. Gromova 1.2 , I.Yu. Torshin 2 , L.E. Fedotova 1
1 FSBEI in the "Ivanovo State Medical Academy", Ivanovo;
2 FSBI "Federal Research Center" Informatics and Management "of the Russian Academy of Sciences, Moscow
Place of publication:
neurology, neuropsychiatry, psychosomatics, 2017, No. 9
Summary:
The purpose of the study is a comprehensive assessment by means of pharmacinformation profiling of all possible effects of mexidol molecules, alfoseta choline, piracetam, glycine, semax in accordance with anatomical and therapy-chemical classification. Material and methods. Hemoreactomic, pharmacinformation and geronto -informational analyzes of the properties of molecules are based on a chemorectic methodology. For chemoreactic analysis, information from the databases Pubchem, HMDB and String was used; For pharmacinformation analysis - information from the international classification of ATX and a combined data selection from the TTD (Therapeutic Target Database), Supertarget, Matador (Manually Annoted Targets and Drugs Online Resource) and PDTD (Potential Drugs Database); For gerontoinformation analysis, data on the heroroprotective action of individual substances from the Pubchem database and the literature on Heroproteus from the Pubmed base, collected through the system of artificial intelligence. Results and discussion. Mexidol is characterized by a maximum set of positive effects (a drug for the treatment of central nervous system diseases, cardiovascular pathology, metabolic disorders, which has anti-inflammatory and anti-infectious properties, etc.). Mexidol and glycine predict the smallest frequencies of such side effects as itching, constipation, paresthesia, vomiting, etc. Geronto -information assessments of changes in the life expectancy of model organisms showed that Mexidol helps to increase the average life expectancy of C. Elegans (by 22.7 ± 10%) , Drosophiles (by 14.4 ± 15%) and mice (by 14.6 ± 3%, control drugs - not more than 6.1%). Conclusion. The results of the study indicate the high potential of Mexidol for use as a hero of the Heroprotector.
Information is intended for medical and pharmaceutical workers. This information cannot serve as a replacement for a doctor’s consultation.
Source of photos and images Shutterstock.com